Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib (Tasigna) in Pulmonary Arterial Hypertension – 24-week Randomized Double-blind Placebo-controlled Phase 2 Trial
2010-019883-36Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Nilotinib (Tasigna) with Placebo (2 arms). Primary endpoint: Pulmonary vascular resistance (PVR). Started Jul 2010; status: terminated.
02
Drugs
nilotinib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2010-019883-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019883-36.